GKOS

152.72

1.52% -2.35

Handel nachbörslich: 152.72

Glaukos Corp (GKOS)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$155.07

Offen:

$154.05

24-Stunden-Volumen:

672.33K

Relative Volume:

0.69

Marktkapitalisierung:

$8.97B

Einnahmen:

$551.35M

Nettoeinkommen (Verlust:

$-189.33M

KGV:

-46.40

EPS:

-3.2916

Netto-Cashflow:

$-35.09M

1W Leistung:

+2.95%

1M Leistung:

+24.68%

6M Leistung:

+35.25%

1J Leistung:

+43.33%

1-Tages-Spanne:

$143.11

$156.60

1-Wochen-Bereich:

$143.11

$156.60

52-Wochen-Spanne:

$73.16

$156.60

Glaukos Corp Stock (GKOS) Company Profile

Firmenname

Glaukos Corp

Sektor

Healthcare (1096)

Branche

Medical Devices (140)

Telefon

949-367-9600

Adresse

1 GLAUKOS WAY, ALISO VIEJO, CA

Mitarbeiter

1,094

Twitter

@GlaukosCorp

Nächster Verdiensttermin

2026-07-29

Neueste SEC-Einreichungen

GKOS's Discussions on Twitter

Compare GKOS vs ABT, SYK, MDT, BSX, EW

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
GKOS Glaukos Corp	152.72	8.97B	551.35M	-189.33M	-35.09M	-3.2916
ABT Abbott Laboratories	93.93	163.61B	45.13B	6.28B	7.38B	3.5895
SYK Stryker Corp	329.78	126.42B	25.27B	3.34B	4.57B	8.6334
MDT Medtronic Plc	83.87	107.36B	36.36B	4.84B	5.43B	3.7212
BSX Boston Scientific Corp	44.77	66.54B	20.62B	3.56B	3.48B	2.3847
EW Edwards Lifesciences Corp	92.21	53.09B	6.30B	1.07B	1.09B	1.8406

Glaukos Corp Stock (GKOS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-10-27	Hochstufung	Wells Fargo	Equal Weight → Overweight
2025-10-01	Eingeleitet	Goldman	Buy
2025-05-01	Herabstufung	Wells Fargo	Overweight → Equal Weight
2025-02-19	Hochstufung	Mizuho	Neutral → Outperform
2024-12-11	Hochstufung	Citigroup	Neutral → Buy
2024-12-06	Eingeleitet	UBS	Buy
2024-12-02	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2024-07-10	Herabstufung	Citigroup	Buy → Neutral
2024-05-06	Hochstufung	Jefferies	Hold → Buy
2023-12-21	Hochstufung	JP Morgan	Neutral → Overweight
2023-12-04	Eingeleitet	Morgan Stanley	Equal-Weight
2023-11-28	Eingeleitet	Truist	Buy
2023-11-08	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-06-07	Hochstufung	Piper Sandler	Neutral → Overweight
2022-12-22	Eingeleitet	Mizuho	Neutral
2022-12-19	Hochstufung	JP Morgan	Underweight → Neutral
2022-12-12	Hochstufung	Citigroup	Neutral → Buy
2022-10-14	Fortgesetzt	Stephens	Overweight
2022-10-04	Eingeleitet	Needham	Buy
2022-07-12	Hochstufung	Stifel	Hold → Buy
2022-02-03	Hochstufung	William Blair	Mkt Perform → Outperform
2022-01-19	Hochstufung	Wells Fargo	Underweight → Equal Weight
2022-01-18	Hochstufung	BTIG Research	Neutral → Buy
2021-11-03	Hochstufung	Stephens	Equal-Weight → Overweight
2021-07-26	Herabstufung	Stephens	Overweight → Equal-Weight
2021-07-20	Herabstufung	Wells Fargo	Equal Weight → Underweight
2021-07-14	Herabstufung	Oppenheimer	Outperform → Perform
2021-07-14	Herabstufung	William Blair	Outperform → Mkt Perform
2021-04-08	Hochstufung	Oppenheimer	Perform → Outperform
2021-01-29	Herabstufung	Piper Sandler	Overweight → Neutral
2020-12-16	Hochstufung	Citigroup	Sell → Neutral
2020-12-09	Eingeleitet	Oppenheimer	Perform
2020-11-17	Hochstufung	Wells Fargo	Underweight → Equal Weight
2020-10-08	Herabstufung	JP Morgan	Neutral → Underweight
2020-06-15	Eingeleitet	Jefferies	Hold
2020-03-05	Eingeleitet	Citigroup	Sell
2020-02-28	Herabstufung	JP Morgan	Overweight → Neutral
2020-01-06	Hochstufung	Berenberg	Hold → Buy
2019-12-12	Herabstufung	Wells Fargo	Outperform → Underperform
2019-09-30	Herabstufung	BofA/Merrill	Buy → Underperform
2019-03-08	Eingeleitet	BTIG Research	Neutral
2018-08-30	Eingeleitet	Berenberg	Hold
2018-08-29	Hochstufung	JP Morgan	Neutral → Overweight
2018-08-03	Bestätigt	Stifel	Hold
2018-06-21	Herabstufung	JP Morgan	Overweight → Neutral
2018-04-13	Herabstufung	Stifel	Buy → Hold
2018-03-01	Bestätigt	Cantor Fitzgerald	Buy
2017-03-02	Bestätigt	Cantor Fitzgerald	Overweight
2017-01-06	Hochstufung	Stifel	Hold → Buy
2016-10-27	Eingeleitet	Wells Fargo	Outperform

Alle ansehen

Glaukos Corp Aktie (GKOS) Neueste Nachrichten

Jul 10, 2026

Midday Stock Roundup: Alignment Healthcare Up 7.8% Ahead of Q2 Results - Orange County Business Journal

Jul 09, 2026

Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise - Stock Titan

Jul 09, 2026

Jul 08, 2026

Glaukos Corp CFO Alex Thurman sells $1.5m in shares - Investing.com

Jul 08, 2026

Form 4 Glaukos Corp For: 8 July By Investing.com - Investing.com Nigeria

Jul 08, 2026

Glaukos chief development officer Navratil sells $99,566 stock By Investing.com - Investing.com Nigeria

Jul 08, 2026

Glaukos (GKOS) CFO executes pre-planned share sale and option exercise - Stock Titan

Jul 08, 2026

Glaukos chief development officer Navratil sells $99,566 stock - Investing.com

Jul 08, 2026

Glaukos (GKOS) chief development officer sells 716 shares under 10b5-1 plan - Stock Titan

Jul 08, 2026

Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool

Jul 08, 2026

GKOS Maintained by Citigroup -- Price Target Raised to $175 - GuruFocus

Jul 08, 2026

GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally? - Yahoo Finance

Jul 08, 2026

Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 - Business Wire

Jul 08, 2026

Jul 07, 2026

Glaukos Corp stock and its role in eye disease treatment - ad-hoc-news.de

Jul 07, 2026

Jul 06, 2026

Form 144 GLAUKOS Corp For: 6 July By Investing.com - Investing.com Nigeria

Jul 06, 2026

Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares - Stock Titan

Jul 06, 2026

Glaukos stock rating reiterated at Outperform by William Blair - Investing.com

Jul 06, 2026

Jul 02, 2026

Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment - Quiver Quantitative

Jul 02, 2026

Glaukos stock hits 52-week high at 148.12 USD By Investing.com - Investing.com Nigeria

Jul 02, 2026

Glaukos stock hits 52-week high at 148.12 USD - Investing.com

Jul 02, 2026

Jul 01, 2026

Form 144 GLAUKOS Corp For: 1 July - Investing.com UK

Jul 01, 2026

Form 144 GLAUKOS Corp For: 1 July By Investing.com - Investing.com Canada

Jul 01, 2026

GKOS (GKOS) insider sells 3,630 shares total across April and June 2026 - Stock Titan

Jul 01, 2026

GKOS Reiterated by Piper Sandler -- Price Target Maintained at $165 - GuruFocus

Jul 01, 2026

Piper Sandler reiterates Glaukos stock rating on iDose headwinds By Investing.com - Investing.com Nigeria

Jul 01, 2026

Piper Sandler reiterates Glaukos stock rating on iDose headwinds - Investing.com

Jul 01, 2026

Jun 29, 2026

Form 4 Glaukos Corp For: 29 June By Investing.com - Investing.com South Africa

Jun 29, 2026

Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding - Stock Titan

Jun 29, 2026

Form 4 Glaukos Corp For: 29 June - Investing.com UK

Jun 29, 2026

Glaukos (NYSE: GKOS) president has 1,056 shares withheld for taxes - Stock Titan

Jun 29, 2026

Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares - Stock Titan

Jun 29, 2026

Jun 27, 2026

Enterprise value to EBIT forward of Glaukos Corp – XETR:6GJ - TradingView

Jun 27, 2026

Jun 26, 2026

Price to book forward of Glaukos Corp – XETR:6GJ - TradingView

Jun 26, 2026

Enterprise value to EBITDA forward of Glaukos Corp – XETR:6GJ - TradingView

Jun 26, 2026

Jun 25, 2026

Goldman Sachs Small Cap Equity Insights Fund's Glaukos Corp(GKOS) Holding History - GuruFocus

Jun 25, 2026

Glaukos Corp Actuals & Estimates (NYSE:GKOS) - TradingView

Jun 25, 2026

Glaukos Moves Into Demodex Blepharitis Space - Orange County Business Journal

Jun 25, 2026

Glaukos completes enrollment in phase 2 blepharitis study - Investing.com

Jun 25, 2026

Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis - BioSpace

Jun 25, 2026

Glaukos completes enrollment in phase 2 blepharitis study By Investing.com - Investing.com Australia

Jun 25, 2026

Glaukos (GKOS) Completes Patient Enrollment in GLK-321 Study - GuruFocus

Jun 25, 2026

Glaukos fills 275-patient trial of eyelid-disease drug candidate - Stock Titan

Jun 25, 2026